Eric Kuhn1, Esther I Schwarz1, Daniel J Bratton1, Valentina A Rossi1, Malcolm Kohler2. 1. Sleep Disorders Center and Pulmonary Division, University Hospital of Zurich, Zurich, Switzerland. 2. Sleep Disorders Center and Pulmonary Division, University Hospital of Zurich, Zurich, Switzerland; Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland; Center for Interdisciplinary Sleep Research, University of Zurich, Zurich, Switzerland. Electronic address: malcolm.kohler@usz.ch.
Abstract
BACKGROUND: Untreated OSA is associated with impaired health-related quality of life (QoL) and excessive daytime sleepiness, which have been shown to improve with treatment. The aim was to compare the effects of CPAP and a mandibular advancement device (MAD) on health-related QoL in OSA. METHODS: MEDLINE and the Cochrane Library were searched up to November 2015 for randomized controlled trials (RCTs) comparing the effect of CPAP, MADs, or an inactive control treatment on health-related QoL assessed by the 36-Item Short Form Health Survey (SF-36) in OSA. Extraction of study characteristics, quality, and bias assessment were independently performed by three authors. A network meta-analysis using multivariate random-effects meta-regression was performed to assess treatment effects on the mental component score (MCS) and the physical component score (PCS) of the SF-36. RESULTS: Of 1,491 identified studies, 23 RCTs were included in the meta-analysis (2,342 patients). Compared with an inactive control, CPAP was associated with a 1.7 point (95% CI, 0.1-3.2; P = .036) improvement in the MCS and a 1.7 point (95% CI, 0.5-2.9; P = .005) improvement in the PCS. MADs were associated with a 2.4 point (95% CI, 0.0-4.9; P = .053) and a 1.5 point (95% CI, -0.2 to 3.2; P = .076) improvement in the MCS and PCS, respectively, compared with inactive control treatments. There were no statistically significant differences between treatment effects of CPAP and MAD on the SF-36 scores. CONCLUSIONS: CPAP is effective in improving health-related QoL in OSA, and MADs may be just as effective, but further RCTs comparing the two treatments are required.
BACKGROUND: Untreated OSA is associated with impaired health-related quality of life (QoL) and excessive daytime sleepiness, which have been shown to improve with treatment. The aim was to compare the effects of CPAP and a mandibular advancement device (MAD) on health-related QoL in OSA. METHODS: MEDLINE and the Cochrane Library were searched up to November 2015 for randomized controlled trials (RCTs) comparing the effect of CPAP, MADs, or an inactive control treatment on health-related QoL assessed by the 36-Item Short Form Health Survey (SF-36) in OSA. Extraction of study characteristics, quality, and bias assessment were independently performed by three authors. A network meta-analysis using multivariate random-effects meta-regression was performed to assess treatment effects on the mental component score (MCS) and the physical component score (PCS) of the SF-36. RESULTS: Of 1,491 identified studies, 23 RCTs were included in the meta-analysis (2,342 patients). Compared with an inactive control, CPAP was associated with a 1.7 point (95% CI, 0.1-3.2; P = .036) improvement in the MCS and a 1.7 point (95% CI, 0.5-2.9; P = .005) improvement in the PCS. MADs were associated with a 2.4 point (95% CI, 0.0-4.9; P = .053) and a 1.5 point (95% CI, -0.2 to 3.2; P = .076) improvement in the MCS and PCS, respectively, compared with inactive control treatments. There were no statistically significant differences between treatment effects of CPAP and MAD on the SF-36 scores. CONCLUSIONS:CPAP is effective in improving health-related QoL in OSA, and MADs may be just as effective, but further RCTs comparing the two treatments are required.
Authors: Thomas Gaisl; Albina Nowak; Noriane A Sievi; Nicolas Gerard; Christian F Clarenbach; Malcolm Kohler; Daniel Franzen Journal: Sleep Breath Date: 2019-04-02 Impact factor: 2.816
Authors: Diego R Mazzotti; Diane C Lim; Kate Sutherland; Lia Bittencourt; Jesse W Mindel; Ulysses Magalang; Allan I Pack; Philip de Chazal; Thomas Penzel Journal: Physiol Meas Date: 2018-09-13 Impact factor: 2.833
Authors: Harneet K Walia; Nicolas R Thompson; Irene Katzan; Nancy Foldvary-Schaefer; Douglas E Moul; Reena Mehra Journal: J Clin Sleep Med Date: 2017-11-15 Impact factor: 4.062
Authors: Katrin Hasselbacher; B Hofauer; J T Maurer; C Heiser; A Steffen; J U Sommer Journal: Eur Arch Otorhinolaryngol Date: 2018-05-28 Impact factor: 2.503
Authors: Stephanie Alison Ward; Elsdon Storey; Robyn L Woods; Garun S Hamilton; Ryo Kawasaki; Andrew L Janke; Matthew T Naughton; Fergal O'Donoghue; Rory Wolfe; Tien Y Wong; Christopher M Reid; Walter P Abhayaratna; Nigel Stocks; Ruth Trevaks; Sharyn Fitzgerald; Lauren A B Hodgson; Liubov Robman; Barbara Workman; John J McNeil Journal: Contemp Clin Trials Date: 2017-10-31 Impact factor: 2.226